Giovanni Parmigiani
乔瓦尼·帕米贾尼
PhD
Professor of Biostatistics, Harvard T.H. Chan School of Public Health; Director, Program in Quantitative Genomics, Dana-Farber Cancer Institute哈佛大学陈曾熙公共卫生学院生物统计学教授；达纳-法伯癌症研究所定量基因组学项目主任
👥Biography 个人简介
Giovanni Parmigiani, PhD is Professor of Biostatistics at the Harvard T.H. Chan School of Public Health and Director of the Program in Quantitative Genomics at Dana-Farber Cancer Institute. He is one of the world's foremost statistical geneticists in cancer risk prediction, best known as a principal developer of the BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) model — the most comprehensive and internationally used tool for estimating breast and ovarian cancer risk in individuals with a family history of these diseases. BOADICEA integrates BRCA1/2 carrier status, polygenic background, epidemiological risk factors, and tumor pathology to provide individualized, calibrated risk estimates that inform decisions about genetic testing referral, surveillance intensity, chemoprevention, and risk-reducing surgery. Professor Parmigiani has also made foundational contributions to Bayesian methods for cancer decision analysis, developing frameworks for optimal decision-making under uncertainty in cancer screening and prevention contexts. His collaborative work spans cancer genomics, somatic mutation pattern analysis, and multi-omic data integration for risk stratification. He has trained dozens of biostatisticians in cancer prevention applications and has authored over 350 peer-reviewed publications, with his BOADICEA-related papers among the most highly cited in clinical genetics literature.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
BOADICEA Model Development and Validation
Co-developed BOADICEA, a multifactorial Bayesian risk model that estimates BRCA1/2 carrier probabilities and absolute breast and ovarian cancer risks from comprehensive pedigree data, incorporating the effects of BRCA1/2 variants, polygenic risk, and familial residual risk. BOADICEA is validated in multiple independent populations across different ethnicities and is now the recommended risk model in multiple national and international clinical guidelines (NICE, NCCN, ASCO) for familial breast and ovarian cancer assessment. The model is implemented in CanRisk — a web-based clinical decision support tool used by thousands of cancer genetics clinicians worldwide.
Bayesian Methods for Cancer Genetic Risk Prediction
Developed and published foundational statistical methodology for Bayesian network-based carrier probability estimation and multifactorial likelihood models that simultaneously account for genetic variants, family history topology, cancer pathology, and epidemiological covariates. These methods, encapsulated in the BayesMendel R package suite, are widely used in research and clinical settings and underpin multiple cancer risk models beyond BOADICEA, including those for Lynch syndrome and other hereditary cancer syndromes.
Polygenic Risk Score Integration into Clinical Risk Models
Led methodological development for integrating polygenic risk scores (PRS) — derived from genome-wide association studies of breast cancer susceptibility loci — into multifactorial clinical risk models. Demonstrated that PRS substantially improves discrimination and calibration of BOADICEA for women without identified high-penetrance mutations, enabling more precise stratification of the much larger population of women with moderate polygenic risk and family history.
Cancer Genomics and Mutation Signature Analysis
Applied Bayesian and machine learning statistical methods to somatic cancer genomics data, developing approaches to identify mutation signatures in cancer genomes that reflect underlying mutational processes (BRCA-deficiency, APOBEC activity, mismatch repair deficiency). These signatures inform prevention and interception strategies by identifying individuals whose tumors arose through preventable or interceptable pathways.
Representative Works 代表性著作
BOADICEA: A Comprehensive Breast Cancer Risk Prediction Model Incorporating Genetic and Nongenetic Risk Factors
Genetics in Medicine (2021)
Latest comprehensive BOADICEA model publication incorporating BRCA1/2, PALB2, CHEK2, ATM, and polygenic risk alongside epidemiological factors for breast and ovarian cancer risk prediction.
The BayesMendel R Package for Cancer Risk Prediction
Cancer Informatics (2013)
Description of BayesMendel, a suite of Bayesian mutation carrier probability models (BRCA-PRO, MMRpro, PancPRO) that form the computational backbone of clinical genetic risk assessment programs worldwide.
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
American Journal of Human Genetics (2019)
Large-scale validation study of polygenic risk scores for breast cancer risk prediction across subtypes, informing their integration into clinical multifactorial models.
A Comprehensive Model for Familial Breast and Ovarian Cancer Covering BRCA1, BRCA2 and Other Susceptibility Genes
Journal of Medical Genetics (2018)
Extension of BOADICEA to include moderate-penetrance genes (PALB2, CHEK2, ATM), providing a more complete multifactorial risk model for the full spectrum of hereditary breast and ovarian cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Faisal Mahmood
Brigham and Women's Hospital; Harvard Medical School
Kun-Hsing Yu
Harvard Medical School; Brigham and Women's Hospital
Ziad Obermeyer
University of California, Berkeley; UC San Francisco
Andrew H. Beck
PathAI; Harvard Medical School (formerly)
关注 乔瓦尼·帕米贾尼 的研究动态
Follow Giovanni Parmigiani's research updates
留下邮箱，当我们发布与 Giovanni Parmigiani（Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment